NAD+ therapy in Australia is a topic of growing public interest, but understanding what it actually is, how (and if) it can be lawfully accessed, and what the evidence shows is critical. This guide covers NAD+ therapy in Australia from an educational perspective only, with reference to official regulatory standards and the latest updates as of August 2026. Nothing here constitutes medical advice or product advertising; all therapeutic decisions rest with a registered Australian doctor after clinical assessment.
What NAD+ Actually Is
NAD+ as a Coenzyme in Cellular Energy Metabolism
Nicotinamide adenine dinucleotide, or NAD+, is a coenzyme present in every cell of the body. Its primary biological role is in energy metabolism, supporting cellular repair processes. NAD+ takes part in the cellular reactions that produce energy and support cellular repair. It is present in every cell of the body and is integral to those metabolic processes.
Why NAD+ Levels Are Studied in the Context of Ageing
NAD+ continues to attract research interest in the context of ageing because it is a coenzyme involved in energy metabolism and cellular repair. Investigation into what role NAD+ plays as organisms age is ongoing, largely at the cellular level. Most of that data remains preclinical or mechanistic, so what it means for human health is not established. Clinical evidence for NAD+ as an anti-ageing or wellness intervention is inconclusive, and long-term human safety data is limited. Research interest is not the same thing as demonstrated benefit, and the distinction matters when reading marketing material about NAD+.
What "NAD+ Therapy" Means in Australia
Compounded Injectable Preparations
NAD+ therapy in Australia often refers to compounded injectable preparations. No injectable NAD+ product is currently included on the Australian Register of Therapeutic Goods (ARTG). When prescribed, these preparations must be compounded for individual patients if, and only if, a registered Australian practitioner independently judges it clinically appropriate. This is determined on a case-by-case basis, not as a blanket approval of the substance or preparation. Any compounded NAD+ preparation has not been evaluated by the TGA for quality, safety, or effectiveness.
IV Infusions Offered by Clinics
There are clinics that promote IV infusions containing NAD+ or related compounds, but these are not approved medicines. The TGA has published a safety alert stating NAD, NAD+, and NADH are not currently permitted ingredients in listed medicines. Products referencing these compounds, if supplied without appropriate AUST L, AUST L(A), or AUST R numbers, may be considered unapproved goods or even illegally supplied. It is crucial to differentiate between lawful, doctor-supervised, individually prescribed compounding, and commercial IV infusions that may not comply with Australian regulations. NAD+ injection therapy in Australia is covered further in a detailed guide.
Oral NMN and Retail Supplements Are a Separate Regulatory Category
Nicotinamide mononucleotide (NMN) is a related molecule. On 10 December 2025, NMN was added to the Permissible Ingredients Determination for listed medicines with strict conditions: oral route only, maximum of 500 mg per day, adults only (not recommended for those pregnant or lactating), and recommended use for 12 weeks or less. Oral NMN or similar supplements are regulated separately from compounded NAD+ injections.
The Regulatory Position in Australia (the Honest Version)
NAD+ Preparations Are Not on the ARTG
No injectable NAD+ product appears on the Australian Register of Therapeutic Goods. Compounded NAD+ preparations have not been evaluated for quality, safety, or therapeutic efficacy by the TGA.
It is important for consumers to understand the practical consequences of a product not being included on the ARTG. When a medicine or supplement is not ARTG-listed, it has not been formally assessed by the TGA for quality, safety, or effectiveness. Products assigned an AUST L or AUST R number have undergone varying levels of scrutiny by the regulator. With unlisted products, the usual regulatory assurances do not apply, and manufacturers or suppliers cannot lawfully advertise or sell them directly to consumers. This is why prescription access, and only through clinical judgement, applies to NAD+ preparations.
What the TGA Safety Alert Says About NAD, NAD+, NADH and NMN
The TGA’s safety alert details that NAD, NAD+, and NADH are not currently permitted as ingredients in listed medicines. Any products or supplements referencing these ingredients, without a valid AUST L, AUST L(A), or AUST R number, could be unapproved or even illegal. The TGA additionally stipulates the new pathway for NMN, strictly for oral use and under precise conditions outlined above.
Why Prescription-Only Means No Direct-to-Consumer Purchase
It is not legal to buy NAD+ preparations directly as a consumer in Australia. Prescription is only possible where a registered Australian medical practitioner assesses the patient’s circumstances and judges a compounded NAD+ preparation clinically appropriate. This prescribing decision always sits with the doctor, not an online platform or commercial entity. The compounded preparation must then be dispensed by a licensed Australian compounding pharmacy and cannot be supplied as an over-the-counter or retail product. For a broader explanation on how to get peptides prescribed in Australia, see our dedicated article.
How GP-Prescribed Access Works Through Telehealth
The Assessment Step
If a patient is considering a general discussion on peptide therapies or related options, the process begins with a telehealth clinic assessment. This is not an assessment for NAD+ therapy specifically, but a medical consultation in which a qualified Australian GP considers the patient’s overall clinical situation. In a standard telehealth consultation, the doctor will ask for a detailed medical history, including any current medications, allergies, long-term health conditions, and relevant family or personal background. The purpose is to build a comprehensive picture of the patient's health and needs. The doctor may also ask about specific symptoms, lifestyle factors, and previous relevant treatments. The appropriateness for any compounded medicine, including NAD+ if relevant, is at the complete discretion of the attending doctor. It is essential to understand that attending a telehealth assessment does not guarantee any prescription will be issued. The doctor's obligation is to make a clinical decision in the patient's best interest based on up-to-date medical standards and safety guidelines. For a deeper dive into how GP-prescribed peptide therapy works in Australia, including case consideration, see our explainer.
The Prescribing Decision Sits With the Doctor, Not the Platform
Only the individual doctor conducting the consultation can ultimately decide if a compounded preparation is clinically appropriate. HPH and similar telehealth services facilitate lawful consultations with registered Australian doctors, but never make clinical decisions or product recommendations; these must be determined by a registered practitioner according to current guidelines and the patient's needs. If required, the doctor will also consider other risk factors, interactions with existing treatments, and regulatory boundaries. Ultimately, a telehealth service acts as a conduit between patient and doctor; it cannot guarantee the outcome of a consultation or the issuing of a prescription. More information is available on what to expect in a peptide telehealth consultation.
Licensed Australian Compounding Pharmacies and Delivery
Should a practitioner determine that a compounded preparation is warranted, the prescription is sent to a licensed Australian compounding pharmacy. This pharmacy operates under national regulatory standards and dispenses the preparation strictly as prescribed. Delivery processes are coordinated directly by the compounding pharmacy and in accordance with all legal standards. Details on what peptide therapy costs in Australia may help those considering different therapy options.
Who Is Not Suitable
Certain groups are categorically excluded from NMN-based supplements by the TGA: pregnant or lactating women, people under 18, and those seeking extended courses (beyond 12 weeks) or doses over 500 mg/day. For compounded NAD+ preparations, suitability is never self-assessed; all other factors are determined only by a registered medical practitioner after individual clinical assessment. Clinical suitability is therefore highly personalised, based on current health, medical history, and the doctor’s assessment. No public information allows a person to self-diagnose suitability or eligibility for NAD+ therapy.
What the Evidence Does and Does Not Show
Human clinical evidence for NAD+ supplementation as an anti-ageing or wellness intervention remains inconclusive. Most available data pertains to cellular or animal models; robust evidence of long-term safety or specific benefits in humans is limited. No efficacy claims, percentages or generalised statements about effectiveness are supported by the current scientific literature.
Questions to Ask Before Starting Anything
- Has the compound or supplement been evaluated by the TGA, and under what conditions is it permitted?
- This question helps clarify if there is any regulatory oversight for the compound or supplement. Only medicines evaluated and approved by the TGA receive an AUST L or AUST R number, which gives certain assurances regarding quality and safety. If the conditions of use are restricted, it is crucial to understand what they are so as not to inadvertently break the law or put health at risk.
- What are the specific safety precautions or exclusions that might apply?
- Therapies and supplements can carry risks that are not immediately obvious, particularly for certain groups such as pregnant or lactating women, younger people, or those with underlying health conditions. Knowing the exclusions protects against harm from unsuitable therapies.
- What does the doctor consider before prescribing a compounded medicine?
- Doctors weigh factors like medical history, current conditions, medications, allergies, and potential interactions. Understanding what is involved underscores the importance of individual assessment, not a "one size fits all" approach.
- What should be monitored during and after therapy if prescribed?
- Any prescription therapy requires ongoing monitoring for side effects, efficacy, and possible complications. This ensures safety and allows swift action if adverse reactions occur.
- Are there alternatives that are approved, and how do they differ in regulatory status or evidence?
- Considering alternatives broadens awareness of other therapies that may carry a stronger evidence base or more robust regulatory approval. Differences in approval status or supporting data often reflect important distinctions in how thoroughly a product has been assessed.
Frequently Asked Questions
What is NAD+?
NAD+ (nicotinamide adenine dinucleotide) is a molecule found in every cell, supporting energy metabolism and cellular repair.
Can NAD+ injections be purchased legally in Australia?
No injectable NAD+ product is available for direct purchase. Only compounded preparations may be prescribed by a registered practitioner when clinically appropriate, and dispensed by a licensed compounding pharmacy.
What did the TGA say about NAD+ therapy?
The TGA’s safety alert states that NAD, NAD+, and NADH are not currently permitted ingredients in listed medicines. Products referencing them without an AUST L, AUST L(A), or AUST R number may be unapproved goods or illegally supplied.
Is there strong clinical evidence for NAD+ therapy?
Human clinical evidence for NAD+ as an anti-ageing or wellness intervention is inconclusive, and long-term safety data is limited.
Can NMN supplements containing NAD+ or NAD+ precursors be bought retail?
Oral NMN supplements are permitted under strict conditions: for adults only, maximum 500 mg per day, oral use only, and not recommended for pregnant or lactating women.
Who decides if NAD+ therapy is clinically suitable?
Clinical suitability for any compounded preparation, including NAD+, is always determined by a registered Australian doctor after comprehensive individual assessment. No one else can make this decision.
“The information on this page is strictly educational. NAD+ preparations are not TGA approved, and any compounded medicine may only be prescribed by an Australian doctor after clinical assessment. Nothing on this page constitutes an offer or advertisement of NAD+ therapy. Any medical decision remains at your practitioner’s sole discretion.”